BACKGROUND: Blocking 5α-reductase-mediated testosterone conversion to dihydrotestosterone (DHT) with finasteride or dutasteride is the driving hypothesis behind two prostate cancer prevention trials. Factors affecting intracellular androgen levels and the androgen receptor (AR) signaling axis need to be examined systematically in order to fully understand the outcome of interventions using these drugs. METHODS: The expression of three 5α-reductase isozymes, as determined by immunohistochemistry and qRT-PCR, was studied in five human prostate cancer cell lines. Intracellular testosterone and DHT were analyzed using mass spectrometry. A luciferase reporter assay and AR-regulated genes were used to evaluate the modulation of AR activity. RESULTS: Prostate cancer cells were capable of accumulating testosterone to a level 15-50 times higher than that in the medium. The profile and expression of 5α-reductase isozymes did not predict the capacity to convert testosterone to DHT. Finasteride and dutasteride were able to depress testosterone uptake in addition to lowering intracellular DHT. The inhibition of AR activity following drug treatment often exceeded the expected response due to reduced availability of DHT. The ability to maintain high intracellular testosterone might compensate for the shortage of DHT. CONCLUSIONS: The biological effect of finasteride or dutasteride appears to be complex and may depend on the interplay of several factors, which include testosterone turnover, enzymology of DHT production, ability to use testosterone and DHT interchangeably, and propensity of cells for off-target AR inhibitory effect.
BACKGROUND: Blocking 5α-reductase-mediated testosterone conversion to dihydrotestosterone (DHT) with finasteride or dutasteride is the driving hypothesis behind two prostate cancer prevention trials. Factors affecting intracellular androgen levels and the androgen receptor (AR) signaling axis need to be examined systematically in order to fully understand the outcome of interventions using these drugs. METHODS: The expression of three 5α-reductase isozymes, as determined by immunohistochemistry and qRT-PCR, was studied in five humanprostate cancer cell lines. Intracellular testosterone and DHT were analyzed using mass spectrometry. A luciferase reporter assay and AR-regulated genes were used to evaluate the modulation of AR activity. RESULTS:Prostate cancer cells were capable of accumulating testosterone to a level 15-50 times higher than that in the medium. The profile and expression of 5α-reductase isozymes did not predict the capacity to convert testosterone to DHT. Finasteride and dutasteride were able to depress testosterone uptake in addition to lowering intracellular DHT. The inhibition of AR activity following drug treatment often exceeded the expected response due to reduced availability of DHT. The ability to maintain high intracellular testosterone might compensate for the shortage of DHT. CONCLUSIONS: The biological effect of finasteride or dutasteride appears to be complex and may depend on the interplay of several factors, which include testosterone turnover, enzymology of DHT production, ability to use testosterone and DHT interchangeably, and propensity of cells for off-target AR inhibitory effect.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: G L Andriole; P Humphrey; P Ray; M E Gleave; J Trachtenberg; L N Thomas; C B Lazier; R S Rittmaster Journal: J Urol Date: 2004-09 Impact factor: 7.450
Authors: Jong Park; Lan Chen; Kristin Shade; Philip Lazarus; John Seigne; Stephen Patterson; Mohamed Helal; Julio Pow-Sang Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: N C Kleinstreuer; P Browne; X Chang; R Judson; W Casey; P Ceger; C Deisenroth; N Baker; K Markey; R S Thomas Journal: Reprod Toxicol Date: 2018-09-08 Impact factor: 3.143
Authors: Eddy J Chen; Adam G Sowalsky; Shuai Gao; Changmeng Cai; Olga Voznesensky; Rachel Schaefer; Massimo Loda; Lawrence D True; Huihui Ye; Patricia Troncoso; Rosina L Lis; Philip W Kantoff; Robert B Montgomery; Peter S Nelson; Glenn J Bubley; Steven P Balk; Mary-Ellen Taplin Journal: Clin Cancer Res Date: 2014-10-15 Impact factor: 12.531
Authors: Renjie Jin; Connor Forbes; Nicole L Miller; Douglas Strand; Thomas Case; Justin M Cates; Hye-Young H Kim; Phillip Wages; Ned A Porter; Krystin M Mantione; Sarah Burke; James L Mohler; Robert J Matusik Journal: Prostate Date: 2022-07-12 Impact factor: 4.012
Authors: Michael V Fiandalo; John H Wilton; Krystin M Mantione; Carol Wrzosek; Kristopher M Attwood; Yue Wu; James L Mohler Journal: Prostate Date: 2017-12-01 Impact factor: 4.104
Authors: Li Tang; Qianqian Zhu; Zinian Wang; Clayton M Shanahan; Jeannette T Bensen; Elizabeth T H Fontham; Gary J Smith; Elena A Pop; Gissou Azabdaftari; James L Mohler; Yue Wu Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02-22 Impact factor: 4.090
Authors: Carmen J Zamora-Sánchez; Aylin Del Moral-Morales; Ana M Hernández-Vega; Valeria Hansberg-Pastor; Ivan Salido-Guadarrama; Mauricio Rodríguez-Dorantes; Ignacio Camacho-Arroyo Journal: Int J Mol Sci Date: 2018-03-15 Impact factor: 5.923